Status:

COMPLETED

Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy

Lead Sponsor:

Sumitomo Pharma Co., Ltd.

Conditions:

Diabetic Neuropathy

Eligibility:

All Genders

18-70 years

Phase:

PHASE3

Brief Summary

This is a safety and efficacy trial of ranirestat(AS-3201) which is an aldose reductase inhibitor in patients with diabetic sensorimotor polyneuropathy.

Eligibility Criteria

Inclusion

  • Patients with the following may enter:
  • Clinical signs and symptoms (footpain, numbness, tingling, weakness, etc.) of symmetrical distal Diabetic Sensorimotor Polyneuropathy with diagnosis by Nerve Conduction Tests and/or Quantitative Sensory Test.
  • 18 to 70 years old of either sex and any race
  • Type I or Type II, insulin-dependent or non insulin-dependent diabetes for at least six months prior to study entry
  • Healthy in general
  • No hospitalizations for diabetic control or episodes of ketoacidosis for three months prior to screening
  • Female patients of childbearing potential must have a negative serum pregnancy test

Exclusion

  • Known non-diabetic causes of neuropathic symptoms
  • Diabetic patients with no neuropathy or severe neuropathy
  • Used any Aldose Reductase Inhibitors within one year of screening
  • Clinically significant illness including unstable cardiac, pulmonary, hematologic, hepatic, renal, or neoplastic disease
  • A history of systemic carcinoma within five years of screening
  • A history of epilepsy or serious head injury
  • A history or evidence of drug or alcohol abuse
  • Test positive at screening for hepatitis B surface antigen or hepatitis C antibody or have a history of a positive result, or patients with evidence of significant hepatic insufficiency
  • A history of known or suspected diagnosis of AIDS, or have tested seropositive for HIV antibody or antigen previously

Key Trial Info

Start Date :

October 1 2004

Trial Type :

INTERVENTIONAL

End Date :

September 1 2006

Estimated Enrollment :

500 Patients enrolled

Trial Details

Trial ID

NCT00101426

Start Date

October 1 2004

End Date

September 1 2006

Last Update

January 14 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Toronto General Hospital, University Health Network

Toronto, Ontario, Canada, M5G 2C4